Influence of mycophenolate mofetil (Cellcept) on the progression of diabetic nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-003768-20-AT

Enrollment

Unknown

Registered

2008-06-16

Start date

2008-09-10

Completion date

Unknown

Last updated

2016-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Type 2 with microalbuminuria

Interventions

Trade Name: Cellcept Product Name: Cellcept Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diabetes mellitus Type 2 age 18-65 existing microalbuminuria existing therapy including ACE-inhibitors and/or angiotensin receptor blockers Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pregnancy, malignancy, transplantation, history of recurrent infections and/or tuberculosis, any condition requiring immunosuppressive therapy

Design outcomes

Primary

Measure	Time frame
Main Objective: To show whether mycophenolate mofetil slows the progression of diabetic nephropathy which will be measured as albumin/creatinine ratio in the spot urine. ;Secondary Objective: ;Primary end point(s): Change in albumin/creatinine ratio in the spot urine	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026